Company Overview and News

0
Sector Study: Europe

2018-06-07 seekingalpha
Italy is the focal point of the slowdown, but economic weakness is developing in most countries - even in Germany.
EZU

23
May ETF Asset Report: U.S. Equities Rule

2018-05-31 zacks
Geopolitical tensions, oil price movement and President Trump’s announcements hit the headlines in the month of May. Donald Trump made impactful announcements pertaining to deregulations, trade relations with other countries and sanctions against countries like Iran and Venezuela. Overall, markets remained upbeat barring some occasional dips.
AGG IVV ELY QQQ IEF VOO SPY EZU IVV IWM EEM

8
Profit from Roman Impasse With These Global Inverse ETFs

2018-05-30 zacks
The latest political crisis in Italy roiled the global markets lately, pushed the euro down to a 10-month low and triggered a safe-haven rally. Along with Italy, Spain (for a different reason) is also expecting a snap election soon, spooking investors about the likely instability in the Euro zone and its aftershocks across the global asset classes.
ACWI DIA EZU EDZ SH VGK EFZ AIA SPDN SDOW EEM

0
Political Instability In Italy And Spain And Slowing Business Activity Confront European Markets

2018-05-30 seekingalpha
In the past two weeks, investors have come, belatedly, to recognize the negative implications of the election of a populist government in Italy, the first such government in Western Europe. The possibility of a government collapse in Spain as a result of the main opposition party's call for a vote of no confidence added to investor concerns last week. Leading indicators of Eurozone business activity showed that economic growth in May, while still characterized by IHS Markit as "robust," had slowed for the fourth month in a row.
EWI EZU

0
U.S. Weekly FundFlows Insight Report: Equity Funds Attract Net New Money For The Week In Spite Of Fears Of Inflation And A Trade War

2018-03-16 seekingalpha
For the first week in four, investors were net redeemers of fund assets (including those of conventional funds and ETFs), withdrawing $291 million. However, the headline number was a bit misleading. While fund investors were net redeemers of money market funds (-$24.2 billion), they padded the coffers of equity funds (+$20.4 billion), taxable bond funds (+$3.2 million), and municipal bond funds (+$339 million) for the fund flows week ended March 14, 2018.
QQQ SHV EZU IEFA

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to EZU / iShares MSCI Eurozone ETF on message board site Silicon Investor.

Venezuela - stocks VENEZUELAN FOREIGN AFFAIRS
Venezuelan Elections on Sunday VNT: Venezuela Telecom
CUSIP: 464286608